The rise of Sildenafil initially drove a surge for major pharmaceutical companies, however recent developments present a murky scenario for shareholders. Lower-cost versions are eroding revenue, and persistent legal https://macievute307094.mdkblog.com/47328168/the-blue-pill-and-the-pharmaceutical-industry-a-risky-investment